Protalix Biotherapeutics Inc
$ 2.30
-3.36%
16 Apr - close price
- Market Cap 185,315,000 USD
- Current Price $ 2.30
- High / Low $ 2.37 / 2.28
- Stock P/E N/A
- Book Value 0.60
- EPS -0.08
- Next Earning Report 2026-05-08
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.14 %
- 52 Week High 3.19
- 52 Week Low 1.32
About
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Analyst Target Price
$11.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-13 | 2025-08-14 | 2025-05-08 | 2025-03-12 | 2024-11-04 | 2024-08-14 | 2024-05-10 | 2024-03-14 | 2023-11-06 | 2023-08-07 | 2023-05-04 |
| Reported EPS | -0.07 | 0.03 | -0.04 | -0.05 | 0.09 | 0.03 | -0.03 | -0.06 | -0.07 | -0.04 | 0.21 | -0.05 |
| Estimated EPS | 0.035 | 0.07 | 0.11 | -0.02 | 0.07 | 0.06 | 0.02 | -0.02 | -0.03 | -0.07 | -0.04 | -0.05 |
| Surprise | -0.105 | -0.04 | -0.15 | -0.03 | 0.02 | -0.03 | -0.05 | -0.04 | -0.04 | 0.03 | 0.25 | 0 |
| Surprise Percentage | -300% | -57.1429% | -136.3636% | -150% | 28.5714% | -50% | -250% | -200% | -133.3333% | 42.8571% | 625% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-08 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLX
2026-04-10 20:39:21
This article provides an overview of PROTALIX BIOTHERAPEUTICS INC (PLX) stock, including its current price of $2.38 USD, recent performance, and key statistics. It details the company's technical and fundamental ratings from ChartMill, its latest earnings report, and analyst forecasts. The company's profile highlights its focus on developing recombinant therapeutic proteins using its proprietary plant cell-based expression system.
2026-04-09 18:10:12
Protalix BioTherapeutics (PLX) has received European Commission approval for a new 2 mg/kg every four weeks dosing regimen for pegunigalsidase alfa in Fabry disease, triggering a $25 million milestone payment from Chiesi. Analysts maintain an $11.00 price target based on stable valuation assumptions. The company issued 2026 revenue guidance of $78.0 million to $83.0 million, including the milestone and sales from Elfabrio and Elelyso.
2026-04-05 16:40:07
This article provides a technical analysis of Protalix Biotherapeutics Inc (PLX), indicating a "Neutral" overall consensus based on various indicators. While some moving averages suggest a "Buy" signal, key momentum indicators like RSI and MACD are currently "Neutral." The analysis also outlines support and resistance levels for the stock.
2026-04-05 00:09:42
The article displays the EBIT per share for Protalix Biotherapeutics, Inc. (SWB:PBDA) on the Stuttgart Stock Exchange. It provides financial data, news, community insights, and forecasts for the company. The page is from TradingView, a platform offering various market tools and information.
2026-04-04 07:40:21
This page provides a comprehensive resource for Protalix BioTherapeutics (PLX) SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event forms, and insider trading disclosures. It highlights recent filings from September and August 2025, detailing insider transactions, equity awards, amendments to at-the-market stock deals, prospectus supplements outlining risk factors, and Q2 2025 financial results showing increased revenue. The platform also offers AI-powered summaries and real-time updates for these documents.
2026-03-30 21:38:55
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have filed an amended passive investment disclosure (Schedule 13G/A) for Protalix BioTherapeutics, Inc. (PLX). The filing indicates that the reporting persons beneficially own 3,616,289 shares of Common Stock, representing 4.5% of the class as of March 30, 2026. This stake is classified as passive ownership with shared voting and dispositive power, falling below the 5% threshold that would require different reporting.
